SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (1023)6/10/2005 1:19:40 PM
From: Jibacoa  Respond to of 3722
 
CRXL Had an upgap today as it went over its May 10 H of 20.44 Volume remains moderate at 136Ks

bigcharts.marketwatch.com

It announced today that it has discovered an antibody against the WNV. which seems to be working in animal trials.<g>

Bernard

AMSTERDAM, June 10 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS: Quote, Profile, Research) (CRXL.O: Quote, Profile, Research) said on Friday it had discovered a human antibody for protection against West Nile virus that has proven effective in animal studies.

"Study results have demonstrated that the fully human monoclonal antibody, derived from patients who survived West Nile infection, effectively neutralized the virus in cell culture and fully protected mice from an otherwise lethal infection," Crucell said in a statement.

Crucell shares gained on the news, rising 4.4 percent to 17 euros, their highest level since October 2000, the month of their initial public offering.

The company, which has never reported a profit, has reported significant progress in developing vaccines against Ebola, the West Nile Virus and SARS.

Crucell's West Nile virus vaccine development programme is due to enter clinical trials at the end of this year.

Since appearing in New York in 1999, the West Nile virus has spread by mosquitos throughout the United States. In 2004, there were 2,470 recorded cases of the disease and 88 fatalities caused by a form of encephalitis, or inflammation of the brain.



To: Jibacoa who wrote (1023)6/23/2005 12:30:30 AM
From: Jibacoa  Read Replies (2) | Respond to of 3722
 
ABRX Continues to try to find support above the 3.50 level after its big downgap on May 19.The stock was up today more than 10% and the higher volumes in the last 2 weeks have been to the upside.

As I mentioned, ABRX doesn't have any significant LTD and reportedly has more than $16M in cash. It seems the R/R on ABRX is not bad at this level.

bigcharts.marketwatch.com

Bernard